Announcement • Apr 01

cbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare

cbdMD, Inc. announced the launch of its clinical healthcare channel, positioning the Company to support physicians, health systems, and value-based care organizations as federal policy establishes structured pathways for hemp-derived cannabinoid products within Medicare programs. On March 20, 2026, the Centers for Medicare & Medicaid Services (CMS) published operational guidance activating the Substance Access Beneficiary Engagement Incentive (BEI), an existing incentive mechanism within CMS Innovation Center models, to include eligible hemp-derived cannabinoid products for the first time. Effective April 1, 2026, participating accountable care organizations and oncology practices in select models, including the Enhancing Oncology Model (EOM) and ACO REACH, may furnish eligible hemp-derived products to Medicare patients as part of physician-supervised care. The upcoming LEAD Model also incorporates the BEI framework when it is expected to launch on January 1, 2027. Together these models encompass thousands of physicians and millions of aligned Medicare beneficiaries. The BEI remains a limited, model-specific initiative, not a broad access or reimbursement program, and participating organizations independently determine supplier relationships. cbdMD is entering the clinical channel with a scientific and regulatory platform the Company believes is unmatched in the hemp-derived CBD category. To the Company's knowledge, no other hemp-derived CBD manufacturer has published both OECD-standard preclinical toxicology data and human randomized controlled trial data for its commercial product lines. That foundation includes: Published preclinical safety data: A 90-day subchronic oral toxicity study conducted to OECD 408 guidelines, the international standard used in pharmaceutical safety assessment, demonstrating safety margins significantly above expected human dosing levels. Human clinical evidence: Data from an IRB-approved, randomized, double-blind, placebo-controlled trial confirming safety and tolerability in human subjects. GRAS regulatory status: Self-affirmed Generally Recognized As Safe (GRAS) dossiers supporting key product categories, the same safety standard applied to conventional food and supplement ingredients reviewed by the FDA. Healthcare-grade supply chain: Batch-level traceability, certificate of analysis documentation, and quality systems designed for institutional procurement and compliance review. In parallel, cbdMD is developing a dedicated provider-focused product line with formulations, documentation, and labeling structured specifically for clinical environments, along with infrastructure to support multi-site health systems and value-based care organizations. The Company is actively engaging accountable care organizations, oncology practices, and health systems as they evaluate implementation under the BEI and broader clinical integration of cannabinoid products. cbdMD believes that provider adoption in this channel will be driven by demonstrated safety, data transparency, and operational reliability; standards the Company has been building toward for years. The company is also pursuing research partnerships with healthcare organizations and academic institutions to generate real-world outcomes data on hemp CBD in physician-supervised Medicare settings. cbdMD is also monitoring the FDA's recent submission of updated regulatory considerations for hemp-derived CBD products to the White House Office of Information and Regulatory Affairs, which the Company views as part of a continued shift toward a more clearly defined, evidence-based federal framework for cannabinoid products. Healthcare organizations interested in cbdMD's clinical channel, product documentation, or supply capabilities are encouraged to contact the Company directly. The Substance Access Beneficiary Engagement Incentive, effective April 1, 2026, allows participating organizations in CMS Innovation Center models — including ACO REACH, the Enhancing Oncology Model, and the upcoming LEAD Model — to furnish eligible hemp-derived CBD products to Medicare patients through physician-supervised consultations. CMS does not reimburse product costs, does not designate preferred or approved suppliers, and does not cover products as a Medicare benefit. Participating organizations make independent clinical and procurement decisions.

cbdMD, Inc. Stock Price

YCBD Share Price Performance

YCBD Community Narratives

Hemp-Derived CBD And Functional Beverages Will Drive Long-Term Market Share Gains

Hemp-Derived CBD And Functional Beverages Will Drive Long-Term Market Share Gains

Trending Discussion

Recently Updated Narratives

Hemp-Derived CBD And Functional Beverages Will Drive Long-Term Market Share Gains

Snowflake Analysis

cbdMD, Inc. Key Details

About YCBD

Recent YCBD News & Updates

cbdMD, Inc. to Report Q2, 2026 Results on May 14, 2026

cbdMD, Inc. Announces Launch of Clinical Healthcare Channel to Support First Federal Pathway for Hemp-Derived CBD in Medicare

New major risk - Financial position

Recent updates

cbdMD, Inc. Competitors

Traws Pharma

Cadrenal Therapeutics

Galera Therapeutics

Ernexa Therapeutics